Comparative Pharmacology
Head-to-head clinical analysis: LIQUID E Z PAQUE versus RENO 60.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUID E Z PAQUE versus RENO 60.
LIQUID E-Z-PAQUE vs RENO-60
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barium sulfate is a radiopaque agent that coats the mucosal surface of the gastrointestinal tract, attenuating X-rays and providing contrast on imaging studies.
RENO-60 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolality iodinated contrast agent. It attenuates X-rays by blocking photons due to the high atomic number of iodine, thereby enhancing vascular and tissue contrast. It distributes in extracellular fluid and is excreted unchanged by glomerular filtration.
Oral: 25-50 mL (barium sulfate 60% w/v) as a single dose for upper GI series; for double-contrast studies, 100-200 mL (barium sulfate 250% w/v) as a single dose. Rectal: For barium enema, 200-300 mL of a 15-20% w/v suspension instilled via enema tube.
Intravenous administration of 0.5-1.0 mL/kg (up to 150 mL total) per radiographic procedure. Dose may be repeated once if needed.
None Documented
None Documented
Not applicable (non-systemic agent); plasma half-life not clinically relevant.
Terminal elimination half-life approximately 30-60 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Primarily fecal (oral route, unabsorbed); negligible renal excretion (<1% as intact drug).
Primarily renal excretion via glomerular filtration; up to 20% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent